Recent studies have underscored the importance of gamma-delta (γδ) T cells in mediating potent MHC-unrestricted cytotoxicity in numerous malignancies. Here, we analyzed Vδ1 and Vδ2 γδ T cell subsets in newly diagnosed chronic myeloid leukemia (CML) patients (n = 40) who had initiated tyrosine kinase inhibitor (TKI) therapy including imatinib (n = 22), nilotinib (n = 14) and dasatinib (n = 4). Patient peripheral blood samples were analyzed at diagnosis and monitored prospectively at 3, 6, 12 and 18 months post-TKI. γδ T cells isolated from healthy donors and CML patients were used against K562, LAMA-84 and KYO-1 cell lines and against primary CML cells in cytotoxicity assays. We found large expansions of Vδ1 and Vδ2 T cells in patients at diagnosis compared to age-matched healthy donors (n = 40) (p < 0.0001). The γδ T cell reconstitution in patients on imatinib and also on nilotinib showed significant reductions of Vδ1 T cell and Vδ2 T cell absolute counts at 3 months compared to diagnosis. Importantly, Vδ1 and Vδ2 T absolute cell counts remained at normal levels from 3 months throughout the follow-up. Next, we observed susceptibility to specific lysis of primary CML tumor cells by Vδ1 T cells from healthy donors. Furthermore, we determined inherent cytotoxic reactivity by autologous patients' Vδ1 T lymphocytes against primary CML tumor cells. Finally, the TCR clonality profiles showed in CML patients mostly polyclonal repertoires regardless of the TKI. Our results provide further evidence into γδ T cell antileukemia immunity in CML that might be beneficial for long-term disease control and treatment outcome.

Department of Internal Medicine Hematology and Oncology Masaryk University and Faculty Hospital Brno Brno Czech Republic

Faculty of Medicine Department of Pathological Physiology Masaryk University Brno Czech Republic

Institute of Hematology and Blood Transfusion Prague Czech Republic

Zobrazit více v PubMed

Deininger MW, Goldman JM, Melo JV. The molecular biology of chronic myeloid leukemia. Blood. 2000;96:3343–3356. doi: 10.1182/blood.V96.10.3343. PubMed DOI

Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and giemsa staining. Nature. 1973;243:290–293. doi: 10.1038/243290a0. PubMed DOI

EMA (2018) Imatinib medac. In: European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/imatinib-medac. Accessed 21 Aug 2022

EMA (2018) Sprycel. In: European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/sprycel. Accessed 21 Aug 2022

EMA (2018) Tasigna. In: European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/tasigna. Accessed 21 Aug 2022

EMA (2018) Bosulif. In: European medicines agency. https://www.ema.europa.eu/en/medicines/human/EPAR/bosulif. Accessed 21 Aug 2022

Druker BJ, Guilhot F, O’Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006;355:2408–2417. doi: 10.1056/NEJMoa062867. PubMed DOI

Chu S, McDonald T, Lin A, et al. Persistence of leukemia stem cells in chronic myelogenous leukemia patients in prolonged remission with imatinib treatment. Blood. 2011;118:5565–5572. doi: 10.1182/blood-2010-12-327437. PubMed DOI PMC

Chomel J-C, Bonnet M-L, Sorel N, et al. Leukemic stem cell persistence in chronic myeloid leukemia patients with sustained undetectable molecular residual disease. Blood. 2011;118:3657–3660. doi: 10.1182/blood-2011-02-335497. PubMed DOI PMC

Rousselot P, Huguet F, Rea D, et al. Imatinib mesylate discontinuation in patients with chronic myelogenous leukemia in complete molecular remission for more than 2 years. Blood. 2007;109:58–60. doi: 10.1182/blood-2006-03-011239. PubMed DOI

Hayday AC. [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000;18:975–1026. doi: 10.1146/annurev.immunol.18.1.975. PubMed DOI

Vantourout P, Hayday A. Six-of-the-best: unique contributions of γδ T cells to immunology. Nat Rev Immunol. 2013;13:88–100. doi: 10.1038/nri3384. PubMed DOI PMC

Knight A, Madrigal AJ, Grace S, et al. The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation. Blood. 2010;116:2164–2172. doi: 10.1182/blood-2010-01-255166. PubMed DOI

Catellani S, Poggi A, Bruzzone A, et al. Expansion of Vdelta1 T lymphocytes producing IL-4 in low-grade non-Hodgkin lymphomas expressing UL-16-binding proteins. Blood. 2007;109:2078–2085. doi: 10.1182/blood-2006-06-028985. PubMed DOI

Kunzmann V, Wilhelm M. Anti-lymphoma effect of gammadelta T cells. Leuk Lymphoma. 2005;46:671–680. doi: 10.1080/10428190500051893. PubMed DOI

Castella B, Foglietta M, Sciancalepore P, et al. Anergic bone marrow Vγ9Vδ2 T cells as early and long-lasting markers of PD-1-targetable microenvironment-induced immune suppression in human myeloma. Oncoimmunology. 2015;4:e1047580. doi: 10.1080/2162402X.2015.1047580. PubMed DOI PMC

Coscia M, Vitale C, Peola S, et al. Dysfunctional Vγ9Vδ2 T cells are negative prognosticators and markers of dysregulated mevalonate pathway activity in chronic lymphocytic leukemia cells. Blood. 2012;120:3271–3279. doi: 10.1182/blood-2012-03-417519. PubMed DOI

Lamb LS, Henslee-Downey PJ, Parrish RS, et al. Increased frequency of TCR gamma delta + T cells in disease-free survivors following T cell-depleted, partially mismatched, related donor bone marrow transplantation for leukemia. J Hematother. 1996;5:503–509. doi: 10.1089/scd.1.1996.5.503. PubMed DOI

Meeh PF, King M, O’Brien RL, et al. Characterization of the gammadelta T cell response to acute leukemia. Cancer Immunol Immunother. 2006;55:1072–1080. doi: 10.1007/s00262-005-0094-6. PubMed DOI PMC

Poggi A, Venturino C, Catellani S, et al. Vdelta1 T lymphocytes from B-CLL patients recognize ULBP3 expressed on leukemic B cells and up-regulated by trans-retinoic acid. Cancer Res. 2004;64:9172–9179. doi: 10.1158/0008-5472.CAN-04-2417. PubMed DOI

Lamb LS, Gee AP, Hazlett LJ, et al. Influence of T cell depletion method on circulating gammadelta T cell reconstitution and potential role in the graft-versus-leukemia effect. Cytotherapy. 1999;1:7–19. doi: 10.1080/0032472031000141295. PubMed DOI

Godder KT, Henslee-Downey PJ, Mehta J, et al. Long term disease-free survival in acute leukemia patients recovering with increased gammadelta T cells after partially mismatched related donor bone marrow transplantation. Bone Marrow Transplant. 2007;39:751–757. doi: 10.1038/sj.bmt.1705650. PubMed DOI

Rohon P, Porkka K, Mustjoki S. Immunoprofiling of patients with chronic myeloid leukemia at diagnosis and during tyrosine kinase inhibitor therapy. Eur J Haematol. 2010;85:387–398. doi: 10.1111/j.1600-0609.2010.01501.x. PubMed DOI

Mustjoki S, Auvinen K, Kreutzman A, et al. Rapid mobilization of cytotoxic lymphocytes induced by dasatinib therapy. Leukemia. 2013;27:914–924. doi: 10.1038/leu.2012.348. PubMed DOI

Wu KN, Wang YJ, He Y, et al. Dasatinib promotes the potential of proliferation and antitumor responses of human γδT cells in a long-term induction ex vivo environment. Leukemia. 2014;28:206–210. doi: 10.1038/leu.2013.221. PubMed DOI

Kreutzman A, Juvonen V, Kairisto V, et al. Mono/oligoclonal T and NK cells are common in chronic myeloid leukemia patients at diagnosis and expand during dasatinib therapy. Blood. 2010;116:772–782. doi: 10.1182/blood-2009-12-256800. PubMed DOI

Kreutzman A, Rohon P, Faber E, et al. Chronic myeloid leukemia patients in prolonged remission following interferon-α monotherapy have distinct cytokine and oligoclonal lymphocyte profile. PLoS ONE. 2011;6:e23022. doi: 10.1371/journal.pone.0023022. PubMed DOI PMC

Siegers GM, Felizardo TC, Mathieson AM, et al. Anti-leukemia activity of in vitro-expanded human gamma delta T cells in a xenogeneic Ph+ Leukemia model. PLoS One. 2011;6:e16700. doi: 10.1371/journal.pone.0016700. PubMed DOI PMC

D’Asaro M, La Mendola C, Di Liberto D, et al. V gamma 9V delta 2 T lymphocytes efficiently recognize and kill zoledronate-sensitized, imatinib-sensitive, and imatinib-resistant chronic myelogenous leukemia cells. J Immunol. 2010;184:3260–3268. doi: 10.4049/jimmunol.0903454. PubMed DOI

Knight A, Mackinnon S, Lowdell MW. Human Vdelta1 gamma-delta T cells exert potent specific cytotoxicity against primary multiple myeloma cells. Cytotherapy. 2012;14:1110–1118. doi: 10.3109/14653249.2012.700766. PubMed DOI

Jabbour E, Kantarjian H. Chronic myeloid leukemia: 2022 update on diagnosis, therapy, and monitoring. Am J Hematol. 2022;97:1236–1256. doi: 10.1002/ajh.26642. PubMed DOI

Harrington P, Dillon R, Radia D, et al. Chronic myeloid leukaemia patients at diagnosis and resistant to tyrosine kinase inhibitor therapy display exhausted T-cell phenotype. Br J Haematol. 2022 doi: 10.1111/bjh.18302. PubMed DOI PMC

Gentles AJ, Newman AM, Liu CL, et al. The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015;21:938–945. doi: 10.1038/nm.3909. PubMed DOI PMC

Gertner-Dardenne J, Castellano R, Mamessier E, et al. Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. J Immunol. 2012;188:4701–4708. doi: 10.4049/jimmunol.1103710. PubMed DOI

Mahon F-X, Réa D, Guilhot J, et al. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre stop imatinib (STIM) trial. Lancet Oncol. 2010;11:1029–1035. doi: 10.1016/S1470-2045(10)70233-3. PubMed DOI

Rousselot P, Charbonnier A, Cony-Makhoul P, et al. Loss of major molecular response as a trigger for restarting tyrosine kinase inhibitor therapy in patients with chronic-phase chronic myelogenous leukemia who have stopped imatinib after durable undetectable disease. J Clin Oncol. 2014;32:424–430. doi: 10.1200/JCO.2012.48.5797. PubMed DOI

Campiotti L, Suter MB, Guasti L, et al. Imatinib discontinuation in chronic myeloid leukaemia patients with undetectable BCR-ABL transcript level: a systematic review and a meta-analysis. Eur J Cancer. 2017;77:48–56. doi: 10.1016/j.ejca.2017.02.028. PubMed DOI

Saussele S, Richter J, Guilhot J, et al. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial. Lancet Oncol. 2018;19:747–757. doi: 10.1016/S1470-2045(18)30192-X. PubMed DOI

Ilander M, Olsson-Strömberg U, Schlums H, et al. Increased proportion of mature NK cells is associated with successful imatinib discontinuation in chronic myeloid leukemia. Leukemia. 2017;31:1108–1116. doi: 10.1038/leu.2016.360. PubMed DOI PMC

Rea D, Henry G, Khaznadar Z, et al. Natural killer-cell counts are associated with molecular relapse-free survival after imatinib discontinuation in chronic myeloid leukemia: the IMMUNOSTIM study. Haematologica. 2017;102:1368–1377. doi: 10.3324/haematol.2017.165001. PubMed DOI PMC

Deniger DC, Moyes JS, Cooper LJN. Clinical applications of gamma delta T cells with multivalent immunity. Front Immunol. 2014;5:636. doi: 10.3389/fimmu.2014.00636. PubMed DOI PMC

Lo Presti E, Corsale AM, Dieli F, Meraviglia S. γδ cell-based immunotherapy for cancer. Expert Opin Biol Ther. 2019;19:887–895. doi: 10.1080/14712598.2019.1634050. PubMed DOI

Barrett AJ, Savani BN. Does chemotherapy modify the immune surveillance of hematological malignancies? Leukemia. 2009;23:53–58. doi: 10.1038/leu.2008.273. PubMed DOI PMC

Sebestyen Z, Prinz I, Déchanet-Merville J, et al. Translating gammadelta (γδ) T cells and their receptors into cancer cell therapies. Nat Rev Drug Discov. 2020;19:169–184. doi: 10.1038/s41573-019-0038-z. PubMed DOI